Akili, Inc. (AKLI)

Market Cap	18.71M
Revenue (ttm)	1.68M
Net Income (ttm)	-59.49M
Shares Out	78.60M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,776
Open	0.238
Previous Close	0.232
Day's Range	0.233 - 0.254
52-Week Range	0.191 - 1.670
Beta	1.99
Analysts	Buy
Price Target	4.00 (+1,573.64%)
Earnings Date	May 9, 2024

About AKLI

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attent...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: AKLI

Financial Performance

In 2023, Akili's revenue was $1.68 million, an increase of 419.50% compared to the previous year's $323,000. Losses were -$59.49 million, 212.5% more than in 2022.

Analyst Forecast

According to one analyst, the rating for AKLI stock is "Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(1,573.64% upside)

Analyst Consensus: Buy